Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
kz7PZDV8j33rnXUR